CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron

 
• By Sten Stovall

Few expected the positive top-line results from CANTOS showing the Phase III cardiovascular disease study using canakinumab met the primary endpoint. Most want to see the full details being unveiled later in 2017.

cardiovascular system
Novartis said the CANTOS trial in inflammatory cardiovascular disease met the primary endpoint • Source: Shutterstock

More from Clinical Trials

More from R&D